CTMX

4.13

1.23% 0.05

Handel nachbörslich: 4.16 0.03 +0.73%

Cytomx Therapeutics Inc (CTMX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$4.08

Offen:

$4.12

24-Stunden-Volumen:

2.62M

Relative Volume:

0.40

Marktkapitalisierung:

$899.11M

Einnahmen:

$76.20M

Nettoeinkommen (Verlust:

$-17.37M

KGV:

453.85

EPS:

0.0091

Netto-Cashflow:

$-75.81M

1W Leistung:

+1.98%

1M Leistung:

-6.14%

6M Leistung:

-1.43%

1J Leistung:

+327.36%

1-Tages-Spanne:

$4.03

$4.205

1-Wochen-Bereich:

$3.99

$4.38

52-Wochen-Spanne:

$0.9082

$8.21

Cytomx Therapeutics Inc Stock (CTMX) Company Profile

Firmenname

Cytomx Therapeutics Inc

Sektor

Healthcare (1111)

Branche

Biotechnology (621)

Telefon

650.515.3185

Adresse

151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA

Mitarbeiter

Twitter

@cytomxinc

Nächster Verdiensttermin

2026-05-07

Neueste SEC-Einreichungen

CTMX's Discussions on Twitter

Compare CTMX vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CTMX Cytomx Therapeutics Inc	4.13	888.23M	76.20M	-17.37M	-75.81M	0.0091
VRTX Vertex Pharmaceuticals Inc	427.65	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	721.05	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	807.55	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	303.00	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	313.32	33.06B	5.36B	287.73M	924.18M	2.5229

Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-16	Hochstufung	JP Morgan	Neutral → Overweight
2026-01-20	Eingeleitet	Guggenheim	Buy
2025-09-22	Eingeleitet	Cantor Fitzgerald	Overweight
2025-09-17	Fortgesetzt	Barclays	Overweight
2025-07-31	Eingeleitet	Oppenheimer	Outperform
2025-05-15	Hochstufung	H.C. Wainwright	Neutral → Buy
2025-04-14	Fortgesetzt	Piper Sandler	Overweight
2024-05-28	Hochstufung	Piper Sandler	Neutral → Overweight
2024-05-09	Hochstufung	Wedbush	Neutral → Outperform
2024-05-06	Hochstufung	Jefferies	Hold → Buy
2024-04-22	Hochstufung	JP Morgan	Underweight → Neutral
2022-11-14	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2022-07-07	Herabstufung	Jefferies	Buy → Hold
2022-07-07	Herabstufung	Mizuho	Buy → Neutral
2022-07-07	Herabstufung	Piper Sandler	Overweight → Neutral
2022-07-07	Herabstufung	Wedbush	Outperform → Neutral
2022-06-24	Eingeleitet	BMO Capital Markets	Outperform
2022-01-18	Hochstufung	Barclays	Underweight → Overweight
2021-11-15	Eingeleitet	BTIG Research	Buy
2021-05-28	Herabstufung	Barclays	Equal Weight → Underweight
2021-03-29	Eingeleitet	JP Morgan	Overweight
2021-03-23	Hochstufung	Jefferies	Hold → Buy
2020-09-22	Herabstufung	Guggenheim	Buy → Neutral
2020-06-01	Herabstufung	Jefferies	Buy → Hold
2020-05-14	Bestätigt	H.C. Wainwright	Buy
2020-03-24	Hochstufung	Wedbush	Neutral → Outperform
2020-03-04	Eingeleitet	Barclays	Equal Weight
2019-11-20	Eingeleitet	Guggenheim	Buy
2019-11-11	Herabstufung	Wedbush	Outperform → Neutral
2019-06-13	Eingeleitet	Mizuho	Buy
2019-05-14	Eingeleitet	Cantor Fitzgerald	Overweight
2019-03-11	Eingeleitet	Barclays	Overweight
2018-11-26	Eingeleitet	Piper Jaffray	Overweight
2018-10-15	Eingeleitet	Goldman	Neutral
2018-09-13	Eingeleitet	H.C. Wainwright	Buy
2018-06-01	Eingeleitet	SunTrust	Buy
2018-01-05	Eingeleitet	Citigroup	Buy
2017-09-08	Eingeleitet	Wedbush	Outperform
2017-03-27	Eingeleitet	H.C. Wainwright	Buy
2017-03-02	Eingeleitet	Instinet	Buy
2017-01-03	Herabstufung	Oppenheimer	Outperform → Perform
2015-11-02	Eingeleitet	Oppenheimer	Outperform

Alle ansehen

Cytomx Therapeutics Inc Aktie (CTMX) Neueste Nachrichten

May 05, 2026

MSN Money - MSN

May 05, 2026

May 02, 2026

CytomX Therapeutics (CTMX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat

May 02, 2026

Apr 30, 2026

Certain Restricted Stock Units of CytomX Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2026. - marketscreener.com

Apr 30, 2026

170,186,365 Common Stock of CytomX Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2026. - marketscreener.com

Apr 30, 2026

CytomX (NASDAQ: CTMX) proxy adds share capacity and expands equity plans - Stock Titan

Apr 30, 2026

CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026 - Yahoo Finance UK

Apr 30, 2026

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Apr 30, 2026

Apr 27, 2026

HC Wainwright & Co. Upgrades CytomX Therapeutics (CTMX) - MSN

Apr 27, 2026

CytomX stock rises 31% in a month: Here's what you should know - MSN

Apr 27, 2026

Cantor Fitzgerald Initiates Coverage of CytomX Therapeutics (CTMX) with Overweight Recommendation - MSN

Apr 27, 2026

Apr 26, 2026

CytomX Therapeutics launches $250M public offering - MSN

Apr 26, 2026

Apr 25, 2026

Wall Street Zen Downgrades CytomX Therapeutics (NASDAQ:CTMX) to Strong Sell - MarketBeat

Apr 25, 2026

Apr 24, 2026

CytomX Therapeutics (NASDAQ:CTMX) Stock Price Crosses Below 50-Day Moving AverageHere's What Happened - MarketBeat

Apr 24, 2026

Apr 23, 2026

CytomX Therapeutics prices $250M public offering at $5.30 per share - MSN

Apr 23, 2026

CTMX Stock Price, Quote & Chart | CYTOMX THERAPEUTICS INC (NASDAQ:CTMX) - ChartMill

Apr 23, 2026

Apr 22, 2026

CTMX (CytomX Therapeutics Inc.) shares climb over 7 percent despite wider than expected Q4 2025 per share losses.Margin of Safety - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 22, 2026

Small Cap or Megacap: Which Healthcare Stock Is Right for You? - The Motley Fool

Apr 22, 2026

CTMX Forecast, Price Target & Analyst Ratings | CYTOMX THERAPEUTICS INC (NASDAQ:CTMX) - ChartMill

Apr 22, 2026

Apr 21, 2026

Analysts bullish on CytomX Therapeutics (CTMX) as CTMX prices $250 million offering - MSN

Apr 21, 2026

Apr 20, 2026

CytomX (NASDAQ: CTMX) seeks shareholder OK to double authorized shares to 600M - Stock Titan

Apr 20, 2026

CytomX Therapeutics (CTMX) gains analyst confidence on trial progress - MSN

Apr 20, 2026

HC Wainwright & Co. Maintains CytomX Therapeutics (CTMX) Buy Recommendation - MSN

Apr 20, 2026

Apr 19, 2026

CytomX Therapeutics (CTMX) making progress on key metastatic colorectal cancer treatment - MSN

Apr 19, 2026

CytomX Therapeutics Inc Share PriceCTMX, RNS News, Articles, Quotes, & Charts (NASDAQ:CTMX) - Proactive financial news

Apr 19, 2026

Apr 18, 2026

CTMX SEC FilingsCytomx Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 18, 2026

Why CTMX Stock Is Soaring 54% Pre-Market Today? - MSN

Apr 18, 2026

Apr 16, 2026

Point72 (CTMX) reports 10,864,581 shares, a 5.0% holding in CytomX - Stock Titan

Apr 16, 2026

Traders Buy High Volume of CytomX Therapeutics Put Options (NASDAQ:CTMX) - MarketBeat

Apr 16, 2026

CytomX Therapeutics (NASDAQ:CTMX) Stock Price Up 6.3%Time to Buy? - MarketBeat

Apr 16, 2026